Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 01, 2026
DataAggregated Company Financials
Companies7
  • 7D1.3%
  • 3M0.2%
  • 1Y-6.5%
  • YTD-0.2%

Over the last 7 days, the Life Sciences industry has risen 1.3%, driven by gains from Lonza Group of 1.5%. However, the industry is down 6.5% over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 01 Jun 2026CHF 48.7bCHF 10.1bCHF 1.1b38.6x44.7x4.8x
Wed, 29 Apr 2026CHF 46.0bCHF 10.1bCHF 1.1b34.3x40.2x4.5x
Fri, 27 Mar 2026CHF 46.4bCHF 10.1bCHF 1.1b32.3x40.5x4.6x
Sun, 22 Feb 2026CHF 50.1bCHF 10.1bCHF 1.3b32x38.8x5x
Tue, 20 Jan 2026CHF 51.2bCHF 10.6bCHF 1.1b32.6x46.6x4.8x
Thu, 18 Dec 2025CHF 47.6bCHF 10.6bCHF 1.1b27.6x43.3x4.5x
Sat, 15 Nov 2025CHF 49.1bCHF 10.6bCHF 1.1b28.3x44.6x4.6x
Mon, 13 Oct 2025CHF 48.8bCHF 10.6bCHF 1.1b30.7x44.4x4.6x
Wed, 10 Sep 2025CHF 52.6bCHF 10.6bCHF 1.1b32.8x47.8x4.9x
Fri, 08 Aug 2025CHF 52.0bCHF 10.7bCHF 1.1b33.4x45.2x4.9x
Sun, 06 Jul 2025CHF 52.4bCHF 10.1bCHF 1.0b33.6x50.5x5.2x
Tue, 03 Jun 2025CHF 52.6bCHF 10.1bCHF 1.0b30.6x50.6x5.2x
Thu, 01 May 2025CHF 53.9bCHF 10.1bCHF 1.0b30.7x51.9x5.3x
Sat, 29 Mar 2025CHF 53.1bCHF 10.1bCHF 1.0b33.1x51.8x5.3x
Mon, 24 Feb 2025CHF 56.2bCHF 10.1bCHF 1.0b33x54.1x5.6x
Wed, 22 Jan 2025CHF 55.4bCHF 10.2bCHF 943.3m35.5x58.7x5.4x
Fri, 20 Dec 2024CHF 52.2bCHF 10.2bCHF 943.6m36.4x55.4x5.1x
Sun, 17 Nov 2024CHF 52.2bCHF 10.2bCHF 943.5m40.6x55.3x5.1x
Tue, 15 Oct 2024CHF 54.1bCHF 10.2bCHF 943.5m41.4x57.4x5.3x
Thu, 12 Sep 2024CHF 56.7bCHF 10.2bCHF 937.1m44.4x60.5x5.6x
Sat, 10 Aug 2024CHF 57.4bCHF 10.2bCHF 924.0m45.2x62.2x5.6x
Mon, 08 Jul 2024CHF 54.3bCHF 10.3bCHF 1.0b46.3x54.2x5.3x
Wed, 05 Jun 2024CHF 52.2bCHF 10.3bCHF 1.0b42.6x52.1x5.1x
Fri, 03 May 2024CHF 54.0bCHF 10.3bCHF 1.0b43.3x53.9x5.3x
Sun, 31 Mar 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Tue, 27 Feb 2024CHF 50.4bCHF 10.2bCHF 982.3m46.7x51.4x5x
Thu, 25 Jan 2024CHF 42.7bCHF 9.8bCHF 1.5b31.6x28.6x4.4x
Sat, 23 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Mon, 20 Nov 2023CHF 41.5bCHF 9.8bCHF 1.5b29.5x27.8x4.2x
Wed, 18 Oct 2023CHF 46.1bCHF 9.8bCHF 1.5b30.7x30.8x4.7x
Fri, 15 Sep 2023CHF 51.9bCHF 9.8bCHF 1.5b35.1x34.8x5.3x
Sun, 13 Aug 2023CHF 53.2bCHF 9.8bCHF 1.5b35.9x34.4x5.4x
Tue, 11 Jul 2023CHF 55.0bCHF 9.7bCHF 1.6b35.9x33.6x5.7x
Thu, 08 Jun 2023CHF 60.5bCHF 9.7bCHF 1.6b37.5x37x6.3x
Price to Earnings Ratio

37x


Total Market Cap: CHF 60.5bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.3x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.62%
Healthcare-0.71%
Life Sciences1.26%
Clinical Research and Equipment1.26%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 496.200.7%
+CHF 237.5m		-12.7%PE38.1x
TECN Tecan GroupCHF 155.904.4%
+CHF 81.5m		-1.9%PS2.2x
SKAN SKAN GroupCHF 50.106.7%
+CHF 70.8m		-31.0%PE69.2x
XLS Xlife SciencesCHF 23.209.4%
+CHF 11.4m		16.6%PS480.5x

Latest News

LONN
CHF 496.20
Lonza Group
7D
0.7%
1Y
-12.7%
TECN
CHF 155.90
Tecan Group
7D
4.4%
1Y
-1.9%
Narrative Update • May 31

TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential

Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.
BANB
CHF 72.55
Bachem Holding
7D
-7.6%
1Y
44.4%
Narrative Update • May 22

BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside

Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
PPGN
CHF 37.85
PolyPeptide Group
7D
-1.2%
1Y
83.3%
SFZN
CHF 79.45
Siegfried Holding
7D
-1.0%
1Y
-16.6%
Narrative Update • May 17

SFZN: Lowered Expectations And 2026 Guidance Shift Will Support Future Upside Potential

Narrative Update: Siegfried Holding Analysts have adjusted their average price target for Siegfried Holding to CHF 103.91, a change of roughly CHF 0.69. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions informed by the recent mix of higher and lower CHF targets from the Street.
SKAN
CHF 50.10
SKAN Group
7D
6.7%
1Y
-31.0%
Narrative Update • May 15

SKAN: Order Backlog And Dividend Policy Will Support Future Returns

Analysts have kept their CHF 62.50 price target on SKAN Group unchanged, citing a slightly lower discount rate, more cautious assumptions on revenue growth and profit margins, and a higher future P/E multiple in their updated models. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026.
XLS
CHF 23.20
Xlife Sciences
7D
9.4%
1Y
16.6%